An overview of the tumor microenvironment, from cells to complex networks (Review)
- Authors:
- Ovidiu Farc
- Victor Cristea
-
Affiliations: Immunology Department, ‘Iuliu Hatieganu’ University of Medicine and Pharmacy, 400012 Cluj‑Napoca, Romania - Published online on: November 26, 2020 https://doi.org/10.3892/etm.2020.9528
- Article Number: 96
-
Copyright: © Farc et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
 |
|
Egeblad M, Nakasone ES and Werb Z: Tumors as organs: Complex tissues that interface with the entire organism. Dev Cell. 18:884–901. 2010.PubMed/NCBI View Article : Google Scholar | |
|
de Visser KE, Eichten A and Coussens LM: Paradoxical roles of the immune system during cancer development. Nat Rev Cancer. 6:24–37. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Murphy K, Weaver C and Janeway C: Janeway's immunobiology. 9th edition. New York, Garland Science, 2017. | |
|
Xue J, Schmidt SV, Sander J, Draffehn A, Krebs W, Quester I, De Nardo D, Gohel TD, Emde M, Schmidleithner L, et al: Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Immunity. 40:274–288. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Aras S and Zaidi MR: TAMeless traitors: Macrophages in cancer progression and metastasis. Br J Cancer. 117:1583–1591. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Kawai O, Ishii G, Kubota K, Murata Y, Naito Y, Mizuno T, Aokaje K, Saijo N, Nishiwaki Y, Gemma A, et al: Predominant infiltration of macrophages and CD8(+) T cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer. 113:1387–1395. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Ryder M, Ghossein RA, Ricarte-Filho JC, Knauf JA and Fagin JA: Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr Relat Cancer. 15:1069–1074. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Georgoudaki AM, Prokopec KE, Boura VF, Hellqvist E, Sohn S, Östling J, Dahan R, Harris RA, Rantalainen M, Klevebring D, et al: Reprogramming tumor-associated macrophages by antibody targeting inhibits cancer progression and metastasis. Cell Rep. 15:2000–2011. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Phan SH: Biology of fibroblasts and myofibroblasts. Proc Am Thorac Soc. 5:334–337. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Chang HY, Chi JT, Dudoit S, Bondre C, van de Rijn M, Botstein D and Brown PO: Diversity, topographic differentiation, and positional memory in human fibroblasts. Proc Nat Acad Sci USA. 99:12877–12882. 2002.PubMed/NCBI View Article : Google Scholar | |
|
Dumont N, Liu B, Defilippis RA, Chang H, Rabban JT, Karnezis AN, Tjoe JA, Marx J, Parvin B and Tlsty TD: Breast fibroblasts modulate early dissemination, tumorigenesis, and metastasis through alteration of extracellular matrix characteristics. Neoplasia. 15:249–262. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Gascard P and Tlsty TD: Carcinoma-associated fibroblasts: Orchestrating the composition of malignancy. Genes Dev. 30:1002–1019. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Michiels C: Endothelial cell functions. J Cell Physiol. 196:430–443. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Zhang L, Yang N, Park JW, Katsaros D, Franchiolli S, Cao G, O'Brien-Jenkins A, Randall TC, Rubin SC and Coukos G: Tumor-derived vascular endothelial growth factor upregulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. Cancer Res. 63:3403–3412. 2003.PubMed/NCBI | |
|
Konerding MA, Malkusch W, Klapthor B, van Ackern C, Fait E, Hill SA, Parkins C, Chaplin DJ, Presta M and Denekamp J: Evidence for characteristic vascular patterns in solid tumours: Quantitative studies using corrosion casts. Br J Cancer. 80:724–732. 1999.PubMed/NCBI View Article : Google Scholar | |
|
Mócsai A: Diverse novel functions of neutrophils in immunity, inflammation, and beyond. J Exp Med. 210:1283–1299. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, Worthen GS and Albelda SM: Polarization of tumor-associated neutrophil phenotype by TGF-beta: ‘N1’ versus ‘N2’ TAN. Cancer Cell. 16:183–194. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Nozawa H, Chiu C and Hanahan D: Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci USA. 103:12493–12498. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Jensen HK, Donskov F, Marcussen N, Nordsmark M, Lundbeck F and von der Maase H: Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. J Clin Oncol. 27:4709–4717. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Walsh SR, Cook EJ, Goulder F, Justin TA and Keeling NJ: Neutrophil-lymphocyte and ratio as a prognostic factor in colorectal cancer. J Surg Oncol. 91:181–184. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Shamri R, Xenakis JJ and Spencer LA: Eosinophils in innate immunity: An evolving story. Cell Tissue Res. 343:57–83. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Carretero R, Sektioglu IM, Garbi N, Salgado OC, Beckhove P and Hämmerling GJ: Eosinophils orchestrate cancer rejection by normalizin tumor vessels and enhancing infiltration of CD8(+) T cells. Nat Immunol. 16:609–617. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Akdis M, Aab A, Altunbulakli C, Azkur K, Costa RA, Crameri R, Duan S, Eiweger T, Eljaszewicz A, Ferstl R, et al: Interleukins (from IL-1 to IL-38), interferons, transforming growth factor β and TNF-α: Receptors, functions, and roles in diseases. J Allergy Clin Immunol. 138:984–1010. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Mattes J, Hulett M, Xie W, Hogan S, Rottenberg ME, Foster P and Parish C: Immunotherapy of cytotoxic T cell-resistant tumors by T helper 2 cells: An eotaxin and STAT6-dependent process. J Exp Med. 197:387–393. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Tepper RI, Pattengale PK and Leder P: Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell. 57:503–512. 1989.PubMed/NCBI View Article : Google Scholar | |
|
Fernández-Aceñero MJ, Galindo-Gallego M, Sanz J and Aljama A: Prognostic influence of tumor-associated eosinophilic infiltrate in colorectal carcinoma. Cancer. 88:1544–1548. 2000.PubMed/NCBI | |
|
Krystel-Whittemore M, Dileepan KN and Wood JG: Mast cell: A multi-functional master cell. Front Immunol. 6(620)2016.PubMed/NCBI View Article : Google Scholar | |
|
Varricchi G, Galdiero MR, Loffredo S, Marone G, Iannone R, Marone G and Granata F: Are mast cells MASTers in cancer? Front Immunol. 8(424)2017.PubMed/NCBI View Article : Google Scholar | |
|
Oldford SA, Haidl ID, Howatt MA, Leiva CA, Johnston B and Marshall JS: A critical role for mast cells and mast cell-derived IL-6 in TLR2-mediated inhibition of tumor growth. J Immunol. 185:7067–7076. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim W, Nair SW, Xu H, Khuong A, Hoang CD, et al: The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 21:938–945. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Patil RS, Shah SU, Shrikhande SV, Goel M, Dikshit RP and Chiplunkar SV: IL17 producing γδT cells induce angiogenesis and are associated with poor survival in gallbladder cancer patients. Int J Cancer. 139:869–881. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Zhao Y, Niu C and Cui J: Gamma-delta (γδ) T cells: Friend or foe in cancer development? J Transl Med. 16(3)2018.PubMed/NCBI View Article : Google Scholar | |
|
Dhodapkar MV and Kumar V: Type II NKT cells and their emerging role in health and disease. J Immunol. 198:1015–1021. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Terabe M, Matsui S, Noben-Trauth N, Chen H, Watson C, Donaldson DD, Carbone DP, Paul WE and Berzofsky JA: NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol. 1:515–520. 2000.PubMed/NCBI View Article : Google Scholar | |
|
Terabe M and Berzofsky JA: The role of NKT cells in tumor immunity. Adv Cancer Res. 101:277–348. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Yang Q, Goding SR, Hokland ME and Basse PH: Antitumor activity of NK cells. Immunol Res. 36:13–25. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Minetto P, Guolo F, Pesce S, Greppi M, Obino V, Ferretti E, Sivori S, Genova C, Lemoli RM and Marcenaro E: Harnessing NK cells for cancer treatment. Front Immunol. 10(2836)2019.PubMed/NCBI View Article : Google Scholar | |
|
van Beek JJP, Martens AWJ, Bakdash G and de Vries IJM: Innate lymphoid cells in tumor immunity. Biomedicines. 4(7)2016.PubMed/NCBI View Article : Google Scholar | |
|
Eisenring M, vom Berg J, Kristiansen G, Saller E and Becker B: IL-12 initiates tumor rejection via lymphoid tissue-inducer cells bearing the natural cytotoxicity receptor NKp46. Nat Immunol. 11:1030–1038. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Mellman I: Dendritic cells: Master regulators of the immune response. Cancer Immunol Res. 1:145–149. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Lijun Z, Xin Z, Danhua S, Xiaoping L, Jianliu W, Huilan W and Lihui W: Tumor-infiltrating dendritic cells may be used as clinicopathologic prognostic factors in endometrial carcinoma. Int J Gynecol Cancer. 22:836–841. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Ma Y, Shurin GV, Peiyuan Z and Shurin MR: Dendritic cells in the cancer microenvironment. J Cancer. 4:36–44. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Zhan Y and Wu L: Functional regulation of monocyte-derived dendritic cells by microRNAs. Protein Cell. 3:497–507. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Ostroumov D, Fekete-Drimusz N, Saborowski M, Kühnel F and Woller N: CD4 and CD8 T lymphocyte interplay in controlling tumor growth. Cell Mol Life Sci. 75:689–713. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, Bettini ML, Gravano DM, Vogel P, Liu CL, et al: Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 72:917–927. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Ziai J, Gilbert HN, Foreman O, Eastham-Anderson J, Chu F, Huseni M and Kim JM: CD8+ T cell infiltration in breast and colon cancer: A histologic and statistical analysis. PLoS One. 13(e0190158)2018.PubMed/NCBI View Article : Google Scholar | |
|
Durgeau A, Virk Y, Corgnac S and Mami-Chouaib F: Recent advances in targeting CD8 T-cell immunity for more effective cancer immunotherapy. Front Immunol. 9(14)2018.PubMed/NCBI View Article : Google Scholar | |
|
Akbulut G, Özkazanç D and Esendağlı G: Th1 cells in cancer-associated inflammation. Turk J Biol. 41:20–30. 2017. | |
|
Bos R and Sherman LA: CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. Cancer Res. 70:8368–8377. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Fujisawa T, Joshi BH and Puri RK: IL-13 regulates cancer invasion and metastasis through IL-13Rα2 via ERK/AP-1 pathway in mouse model of human ovarian cancer. Int J Cancer. 131:344–356. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Nishimura T, Iwakabe K, Sekimoto M, Ohmi Y, Yahata T, Nakui M, Sato T, Habu S, Tashiro H, Sato M and Ohta A: Distinct role of antigen-specific t helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J Exp Med. 190:617–627. 1999.PubMed/NCBI View Article : Google Scholar | |
|
Lorvik KB, Hammarström C, Fauskanger M, Haabeth OA, Zangani M, Haraldsen G, Bogen B and Corthay A: Adoptive transfer of tumor-specific Th2 cells eradicates tumors by triggering an in situ inflammatory immune response. Cancer Res. 76:6864–6876. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Amicarella F, Muraro MG, Hirt C, Cremonesi E, Padovan E, Mele V, Governa V, Han J, Huber X, Droeseret RA, et al: Dual role of tumour-infiltrating T helper 17 cells in human colorectal cancer. Gut. 66:692–704. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Lee YK, Turner H, Maynard CL, Oliver JR, Chen D, Elson CO and Weaver CT: Late developmental plasticity in the T helper 17 lineage. Immunity. 30:92–107. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S, Huang E, Finlayson E, Simeone D, Welling TH, et al: Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood. 114:1141–1149. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Martin-Orozco N, Muranski P, Chung Y, Yang XO, Yamazaki T, Lu S, Hwu P, Restifo NP, Overwijk WW and Dong C: T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity. 31:787–798. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Lu Y, Hong S, Li H, Park J, Hong B, Wang L, Zheng Y, Liu Z, Xu J, He J, et al: Th9 cells promote antitumor immune responses in vivo. J Clin Invest. 122:4160–4171. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Kim K, Kim G, Kim JY, Yun HJ, Lim SC and Choi HS: Interleukin-22 promotes epithelial cell transformation and breast tumorigenesis via MAP3K8 activation. Carcinogenesis. 35:1352–1361. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Gu-Trantien C, Loi S, Garaud S, Equeter C, Libin M, de Wind A, Ravoet M, Le Buanec H, Sibille C, Manfouo-Foutsop G, et al: CD4' follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest. 123:2873–2892. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Verma A, Mathur R, Farooque A, Kaul V, Gupta S and Dwarakanath BS: T-regulatory cells in tumor progression and therapy. Cancer Manag Res. 11:10731–10747. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Facciabene A, Motz GT and Coukos G: T-regulatory cells: Key players in tumor immune escape and angiogenesis. Cancer Res. 72:2162–2171. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Correale P, Rotundo MS, Del Vecchio MT, Remondo C, Migali C, Ginnaneschi C, Tsang KY, Lichetta A, Manucci S, Loiacono L, et al: Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy. J Immunother. 33:435–441. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Wouters MCA and Nelson BH: Prognostic significance of tumor-infiltrating B cells and plasma cells in human cancer. Clin Cancer Res. 24:6125–6135. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Yuen GJ, Demissie E and Pillai S: B lymphocytes and cancer: A love-hate relationship. Trends Cancer. 2:747–757. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Farc O and Cristea V: Pro-and antitumor role of interleukins 1 to 41. Roum Arch Microbiol Immunol. 78:149–162. 2019. | |
|
Figueras A, Arbos MA, Quiles MT, Viñals F, Germà JR and Capellà G: The impact of KRAS mutations on VEGF-A production and tumour vascular network. BMC Cancer. 13(125)2013.PubMed/NCBI View Article : Google Scholar | |
|
Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ and Harris AL: The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol. 157:411–421. 2000.PubMed/NCBI View Article : Google Scholar | |
|
Hill BS, Sarnella A, D'Avino G and Zannetti A: Recruitment of stromal cells into tumour microenvironment promote the metastatic spread of breast cancer. Semin Cancer Biol. 60:202–213. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Austenaa L and Natoli G: A shortcut for early macrophage recruitment into tumors by activated oncogenes. Genes Dev. 31:223–225. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Mantovani A, Allavena P, Sica A and Balkwill F: Cancer-related inflammation. Nature. 454:436–444. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Wörmann SM, Diakopoulos KN, Lesina M and Algül H: The immune network in pancreatic cancer development and progression. Oncogene. 33:2956–2967. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Le Naour A, Prat M, Thibault B, Mevel R, Lemaître L, Leray H, Joubert MV, Coulson K, Golzio M, Lefevre L, et al: Tumor cells educate mesenchymal stromal cells to release chemoprotective and immunomodulatory factors. J Mol Cell Biol. 12:202–215. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Bosiljcic M, Cederberg RA, Hamilton MJ, LePard NE, Harbourne BT, Collier JL, Halvorsen EC, Shi R, Franks SE, Kim AY, et al: Targeting myeloid-derived suppressor cells in combination with primary mammary tumor resection reduces metastatic growth in the lungs. Breast Cancer Res. 21(103)2019.PubMed/NCBI View Article : Google Scholar | |
|
Dunn GP, Old LJ and Schreiber RD: The three Es of cancer immunoediting. Annu Rev Immunol. 22:329–360. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Casey SC, Li Y and Felsher DW: An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation. Immunol Res. 58:282–291. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Casey SC, Tong L, Li Y, Do R, Walz S, Fitzgerald KN, Gouw AM, Baylot V, Gütgemann I, Eilers M and Felsher DW: MYC regulates the antitumor immune response through CD47 and PD-L1. Science. 352:227–231. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Xiong GF and Xu R: Function of cancer cell-derived extracellular matrix in tumor progression. J Cancer Metastasis Treat. 2:357–364. 2016. | |
|
Agrawal N, Bettegowda C, Cheong I, Geschwind JF, Drake CG, Hipkiss EL, Tatsumi M, Dang LH, Diaz LA Jr, Pomper M, et al: Bacteriolytic therapy can generate a potent immune response against experimental tumors. Proc Natl Acad Sci. 101:15172–15177. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Haabeth OA, Bogen B and Corthay A: A model for cancer - suppressive inflammation. Oncoimmunology. 1:1146–1155. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Schäfer M and Werner S: Cancer as an overhealing wound: An old hypothesis revisited. Nat Rev Mol Cell Biol. 9:628–63879. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Riss J, Khanna C, Koo S, Chandramoulli DV, Yang HH, Hu Y, Kleiner DE, Rosenward A, Schaeffer CF, Ben-Sasson SA, et al: Cancers as wounds that do not heal: Differences and similarities between renal regeneration/repair and renal cell carcinoma. Cancer Res. 66:7216–7224. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Pesic M and Greten FR: Inflammation and cancer: Tissue regeneration gone awry. Curr Opin Cell Biol. 43:55–61. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Naga A, Siddiqui A and Bindu H: Immuno defense mechanism against tumors. J Cancer Sci Ther. 17(2)2011. | |
|
Kondratova M, Czerwinska U, Sompairac N, Amigorena SD, Soumelis V, Barillot E, Zinovyev A and Kuperstein I: A multiscale signalling network map of innate immune response in cancer reveals cell heterogeneity signatures. Nat Commun. 10(4808)2019.PubMed/NCBI View Article : Google Scholar | |
|
Liu Y and Zeng G: Cancer and innate immune system interactions: Translational potentials for cancer immunotherapy. J Immunother. 35:299–308. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Wong R, Pepper C, Brennan P, Nagorsen D, Man S and Fegan C: Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells. Haematologica. 98:1930–1938. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Burkholder B, Huang RY, Burgess R, Luo S, Jones VS, Zhang W, Lu ZQ, Gao CY, Wang BL, Zhang YM and Huang RP: Tumor-induced perturbations of cytokines and immune cell networks. Biochim Biophys Acta. 1845:182–201. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, et al: The immune landscape of cancer. Immunity. 48:812–830.e14. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Ringelhan M, Pfister D, O'Connor T, Pikarsky E and Heikenwalder M: The immunology of hepatocellular carcinoma. Nat Immunol. 19:222–232. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Neagu M, Caruntu C, Constantin C, Boda D, Zurac S, Spandidos DA and Tsatsakis AM: Chemically induced skin carcinogenesis: Updates in experimental models (Review). Oncol Rep. 35:2516–2528. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Boda D, Docea AO, Calina D, Ilie MA, Caruntu C, Zurac S, Neagu M, Constantin C, Branisteanu DE, Voiculescu V, et al: Human papilloma virus: Apprehending the link with carcinogenesis and unveiling new research avenues. Int J Oncol. 52:637–655. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Palucka AK and Coussens LM: The basis of oncoimmunology. Cell. 164:1233–1247. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Ion A, Popa IM, Papagheorghe LM, Lisievici C, Lupu M, Voiculescu V, Caruntu C and Boda D: Proteomic approaches to biomarker discovery in cutaneous T-cell lymphoma. Dis Markers. 2016(9602472)2016.PubMed/NCBI View Article : Google Scholar | |
|
Grigore O, Mihailescu AI, Solomon I, Boda D and Caruntu C: Role of stress in modulation of skin neurogenic inflammation. Exp Ther Med. 17:997–1003. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Solomon I, Voiculescu VM, Caruntu C, Lupu M, Popa A, Ilie MA, Albulescu R, Caruntu A, Tanase C, Constantin C, et al: Neuroendocrine factors and head and neck squamous cell carcinoma: An affair to remember. Dis Markers. 2018(9787831)2018.PubMed/NCBI View Article : Google Scholar | |
|
Caruntu C, Boda D, Constantin C, Caruntu A and Neagu M: Catecholamines increase in vitro proliferation of murine B16F10 melanoma cells. Acta Endocrinol. 10:545–558. 2014. | |
|
Lupu M, Caruntu A, Caruntu C, Papagheorghe LML, Ilie MA, Voiculescu V, Boda D, Constantin C, Tanase C, Sifaki M, et al: Neuroendocrine factors: The missing link in non melanoma skin cancer (Review). Oncol Rep. 38:1327–1340. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Maj E, Papiernik D and Wietrzyk J: Antiangiogenic cancer treatment: The great discovery and greater complexity (Review). Int J Oncol. 49:1773–1784. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Cotechini T, Medler TR and Coussens LM: Myeloid cells as targets for therapy in solid tumors. Cancer J. 21:343–350. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Kruger S, Ilmer M, Kobold S, Cadilha BL, Endres S, Ormanns S, Schuebe G, Renz BW, D'Haese JG, Schloesser H, et al: Advances in cancer immunotherapy 2019 - latest trends. J Exp Clin Cancer Res. 38(268)2019.PubMed/NCBI View Article : Google Scholar | |
|
Farkona S, Diamandis EP and Blasutig IM: Cancer immunotherapy: The beginning of the end of cancer? BMC Med. 14(73)2016.PubMed/NCBI View Article : Google Scholar | |
|
Clancy T and Hovig E: Profiling networks of distinct immune-cells in tumors. BMC Bioinformatics. 17(263)2016.PubMed/NCBI View Article : Google Scholar | |
|
Munks M, Levitsky V, Hill A and Knoetgen H: Cytomegalovirus-specific CD8 T cells kill B16 melanoma cells in vivo whe activated by bifunctional major histocompatibility class I-antibody fusion molecules (pMHCI-IgGs). J Immunotherapy Cancer. 3(237)2015. | |
|
Boda D: Cellomics as integrative omics for cancer. Curr Proteomics. 10:237–245. 2013. | |
|
Ancuceanu R, Dinu M, Neaga I, Laszlo FG and Boda D: Development of QSAR machine learning-based models to forecast the effect of substances on malignant melanoma cells. Oncol Lett. 17:4188–4196. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Robin X, Creixell P, Radetskaya O, Santini CC, Longden J and Linding R: Personalized network-based treatments in oncology. Clin Pharmacol Ther. 94:646–650. 2013.PubMed/NCBI View Article : Google Scholar |
